- Home
- CLLS vs INBX Comparison
CLLS vs INBX Comparison
Compare CLLS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- INBX
- Stock Information
- Founded
- CLLS 1999
- INBX 2010
- Country
- CLLS France
- INBX United States
- Employees
- CLLS N/A
- INBX N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- INBX Health Care
- Exchange
- CLLS Nasdaq
- INBX Nasdaq
- Market Cap
- CLLS 240.2M
- INBX 237.5M
- IPO Year
- CLLS 2007
- INBX 2020
- Fundamental
- Price
- CLLS $1.99
- INBX $15.83
- Analyst Decision
- CLLS Buy
- INBX Hold
- Analyst Count
- CLLS 2
- INBX 1
- Target Price
- CLLS $8.00
- INBX N/A
- AVG Volume (30 Days)
- CLLS 23.2K
- INBX 118.1K
- Earning Date
- CLLS 11-04-2024
- INBX 08-13-2024
- Dividend Yield
- CLLS N/A
- INBX N/A
- EPS Growth
- CLLS N/A
- INBX N/A
- EPS
- CLLS N/A
- INBX 118.83
- Revenue
- CLLS $19,635,000.00
- INBX $1,687,000.00
- Revenue This Year
- CLLS $271.02
- INBX N/A
- Revenue Next Year
- CLLS $33.48
- INBX N/A
- P/E Ratio
- CLLS N/A
- INBX $0.13
- Revenue Growth
- CLLS N/A
- INBX 24.26
- 52 Week Low
- CLLS $0.96
- INBX $10.80
- 52 Week High
- CLLS $3.77
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- CLLS 42.28
- INBX 55.90
- Support Level
- CLLS $1.88
- INBX $14.67
- Resistance Level
- CLLS $2.07
- INBX $16.35
- Average True Range (ATR)
- CLLS 0.10
- INBX 0.65
- MACD
- CLLS -0.02
- INBX -0.09
- Stochastic Oscillator
- CLLS 31.94
- INBX 45.59
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.